Cadila Healthcare climbs over 3 per cent on getting USFDA nod for Macitentan & Ibrutinib capsules

Zydus Cadila has received final approval from USFDA to market Macitentan tablets, 10 mg. It has also received a final nod from USFDA to market Ibrutinib capsules, 70 mg and 140 mg.   

Macitentan is used to manage the symptoms of pulmonary arterial hypertension while Ibrutinib capsule is used to treat certain types of cancers such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and Waldenstrom's macroglobulinemia.  

Reacting to this, the company’s stock today increased by 3.15 per cent and made an intraday high of Rs 475.80 per share at 1.41 pm. 

Besides, the company reported a net profit of Rs 512.50 crore in Q3FY21. It had reported a profit of Rs 364.40 crore in Q3FY20, an increase of 40.64 per cent. The company reported net sales of Rs 3,753.70 crore for Q3FY21, an increase of 6.2 per cent as against the net sales of Rs 3,534.50 crore for Q3FY20.  

According to BSE data, the stock traded at a P/E multiple of 28.96 and a price-to-book ratio of 3.90. The stock has a 52-week high and a 52-week low of Rs 509.35 and Rs 318.10, respectively.  

At 1.54 pm on Thursday, the stock of the company was trading at Rs 474.35, up by 2.76 per cent on BSE.